12 reports

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy
  • Chronic Disease
  • Hospital
  • Therapy
  • Vaccine

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Drug
  • Allergy Immunotherapy
  • Hospital
  • Vaccine

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Chronic Disease
  • Hospital
  • Vaccine

These drugs are useful for treatment of inflammatory diseases, allergy, pain, , asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria etc.

  • Antifungal
  • Hospital
  • Therapy
  • World
  • Sensorion S.A.

The data were presented at the European Academy of Allergy and Clinical Immunology ##th Annual Congress 2016.

  • Antifungal
  • Hospital
  • World
  • Product Initiative
  • Sensorion S.A.

IT WAS ALSO UNDER DEVELOPMENT FORAUTOIMMUNE DISEASES AND ALLERGIES.

  • Acne Treatment
  • Hospital
  • Pharmaceutical
  • Therapy
  • Vaccine

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • Hospital
  • Targeted Therapy
  • Vaccine
  • United States
  • Product Initiative

PI##-KINASE DELTA IS EXPRESSED PRIMARILY IN BLOOD CELL LINEAGES, INCLUDING CELLS THAT CAUSE OR MEDIATE HEMATOLOGIC MALIGNANCIES, INFLAMMATION, AUTOIMMUNE DISEASES AND ALLERGIES.

  • Hospital
  • Lymphoma
  • Vaccine
  • United States
  • Product Initiative

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Hospital
  • Therapy
  • Vaccine
  • United States
  • Product Initiative

This explains the need for a high drug dose of IXF-## as supported by the findings of the recently published post-hoc analysis.

  • Hospital
  • Monoclonal Antibody
  • Therapy
  • Vaccine
  • United States

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antifungal
  • Hospital
  • Vaccine
  • United States
  • SCYNEXIS, Inc.

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Antifungal
  • Clinical Trial
  • Hospital
  • Vaccine
  • AstraZeneca PLC